CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT
Trial Parameters
Brief Summary
The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.
Eligibility Criteria
Inclusion Criteria: Adult and pediatric patients with hematological malignancies in complete remission (CR), partial remission (PR) or with stable disease * Acute myeloid leukemia (AML): * Patients with high-risk AML in first complete remission (CR1) * Patients with relapsed or primary therapy-refractory AML * Acute lymphoid leukemia (ALL): * Patients with high-risk ALL in CR1 * Patients with relapsed or primary refractory ALL * Hodgkin's disease: Patients with relapsed or primary refractory Hodgkin's disease * Non-Hodgkin's lymphoma: Patients with relapsed or primary refractory Non- Hodgkin's lymphoma * Myelodysplastic Syndrome (MDS)/ Myeloproliferative Syndrome (MPS): °Patients with refractory MDS/MPS * Multiple myeloma (MM): Patients with relapsed or refractory multiple myeloma Exclusion Criteria: * Age \>65 years or \<8 weeks * Patients with progressive disease prior hematopoietic cell transplantation (HCT) * \<3 months after preceding HCT * Treatment with T-cell or Interleukin-2 (